Petmed Express opened higher at $1.08, compared with its previous close of $1.07. In the last trading session, the stock traded between $0.93 and $1.08. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Petmed Express is now worth
$ 3.32
Resulting in a loss of
$ 96.68 (96.68%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.08 (-7.61%)
Day High
$1.08
Day Low
$0.93
Day Open
$1.08
Prev Close
$1.07
Volume
3,43,681
1W Return
-20.00%
1M Return
-22.52%
3M Return
-50.30%
6M Return
-56.46%
1Y Return
-63.42%
Market Cap ($ Mn)
22
PE Ratio
-
PB Ratio
1.77
PEG Ratio
-
ROE
-6.70%
ROCE
-0.82%
EPS (TTM)
$-0.28
1 Week
-20.00%
1 Month
-22.52%
3 Months
-50.30%
6 Months
-56.46%
9 Months
-66.87%
PetMed Express Q2FY27 Results: Net loss narrows to $6.4 million
Net loss narrowed to $6.4 million from $8.5 million YoY. Net sales fell 19.4% to $35.8 million due to lower prescription sales. Advertising expenses dropped 52.3% to $2.1 million. Customer acquisition cost decreased 32% YoY to $51 per customer. Adjusted EBITDA loss widened to $3.6 million from $2.3 million.
2 days agoPetMed Express signs deal with Pet Supermarket for pet prescriptions
PetMed Express partners with Pet Supermarket to supply pet prescriptions and health products. The deal leverages PetMeds' ability to ship to all 50 states. Pet Supermarket operates approximately 200 retail stores across the Southeast. Partnership integrates licensed pharmacy services with existing retail platforms.
3 days agoPetMeds grants equity awards to new CEO and CTO as employment inducements
Granted 250,000 restricted shares and 250,000 PSUs to CEO Jeff Willard on September 28, 2026. Issued 100,000 restricted shares to CTO Andrew Parry on October 1, 2026. Awards granted under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment. Restricted stock vests over three years in equal annual increments. PSUs linked to total shareholder return against S&P 600 Specialty Retail Index through 2029.
1mo agoPetMeds appoints Tamar Elkeles as independent director
Tamar Elkeles appointed independent director and Compensation Committee Chair. Effective date is September 17, 2026. Follows appointment of Jeff Willard as CEO and President. Elkeles brings 30+ years experience including tenure at Qualcomm.
1mo agoPetMed Express Q1 loss narrows 82% to $6.1 million as sales fall 19.9%
PetMed Express reported a Q1 net loss of $6.1 million, down 82% YoY, driven by the absence of prior-year impairment charges. Net sales fell 19.9% to $41 million due to lower prescription sales, though recurring revenue share rose to 61.5%. The board is reviewing a $3/share acquisition proposal from Silvercape Investments.
3mo agoPetMeds signs $37 million sale-leaseback deal for headquarters
PetMed Express agrees to sell its Florida headquarters and distribution center for $37 million in a sale-leaseback deal. The transaction aims to unlock value and fund core business growth, with closing expected within 120 days.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $506.04 | +0.32% | $1,05,708.21M | 14.01 | |
| $304.77 | -0.26% | $49,345.01M | 45.36 | |
| $292.97 | +0.93% | $23,316.90M | 10.31 | |
| $72.62 | +0.18% | $14,450.29M | 52.31 | |
| $79.43 | -1.38% | $14,087.55M | - | |
| $142.24 | -0.19% | $13,957.16M | 20.21 | |
| $22.22 | -2.29% | $11,935.03M | 11.93 | |
| $183.50 | +2.35% | $11,542.15M | 15.26 | |
| $186.19 | +0.59% | $10,862.51M | 27.11 | |
| $196.77 | +0.70% | $10,170.65M | 7.00 | |
| $103.03 | -0.49% | $8,522.13M | 34.79 | |
| $50.06 | +1.96% | $7,945.72M | 25.00 |
An investment of $100 made 5 years ago in Petmed Express is now worth
$ 3.32
Resulting in a loss of
$ 96.68 (96.68%)
Note: Past profits do not guarantee future returns.
